Background {#Sec1}
==========

Head and neck cancer (HNC) is currently the fifth most common malignancy worldwide, with \> 600,000 new cases and \> 300,000 deaths annually \[[@CR1], [@CR2]\]. Despite effective surgical interventions and adjuvant therapy, the 5-year HNC survival rate of nearly 50% is still lower than that of most other cancers \[[@CR3]\]. HNC originates in the mucosal epithelium of the oropharynx, nasopharynx, nasal and paranasal sinuses, larynx and hypopharynx. Many patients are diagnosed with HNC at an advanced stage. Data from the United States show that more than two-thirds of HNC patients present with lymph node invasion or distant metastasis at the time of diagnosis. More than half the patients need more surgery or radiotherapy because of recurrence within 2 years of initial surgery \[[@CR4]\]. Therefore, simple, effective and economically feasible laboratory indices that can predict increased risk of recurrence, metastasis or death in HNC patients are essential for early diagnosis and improved survival in clinical practice.

Awareness of the presence of inflammation in the tumor microenvironment has spurred research on the relationship between inflammation and malignancy \[[@CR5]--[@CR10]\]. The progression of cancer requires interactions between tumor cells and their microenvironment, including inflammatory, immune and metabolic responses to stimuli from the surrounding tissue. The systemic inflammatory response plays a key role in tumor cell invasion by promoting microvascular regeneration, tumor metastasis, and tumor cell proliferation \[[@CR8], [@CR9], [@CR11]\]. Moreover, the systemic inflammatory response facilitates the differentiation of tumor cells and suppresses activity of host immune cells \[[@CR6], [@CR12]--[@CR14]\]. Neutrophil-to-lymphocyte ratio (NLR) is an accurate and reliable index of systemic inflammation. NLR is closely associated with prognosis of solid tumors, such as colorectal, non-small cell lung, stomach and prostate cancer \[[@CR15]--[@CR19]\]. However, the association of NLR and prognosis of HNC remains controversial. For that reason, we conducted this meta-analysis of the prognostic value of NLR in HNC.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

A systematic research was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines \[[@CR20]\]. The research of PubMed, Embase, Cochrane Library and Web of Science identified relevant studies published in English or Chinese up to June 2016. The search strings included "head and neck cancer", "head and neck carcinoma", "head and neck neoplasms", "neutrophil-to-lymphocyte ratio", "neutrophils", "lymphocytes", and "NLR". Manual searches of reference lists in articles retrieved online were conducted to identify additional relevant studies.

Literature inclusion and exclusion criteria {#Sec4}
-------------------------------------------

Articles were included following independent searches by two of the authors (YY and XL). Disagreements were resolved by discussion or intervention by a third researcher (HW). To be included, a study had to report findings on the association between prognosis in head and neck tumors and NLR in peripheral blood before therapeutic intervention. The interventions included surgical resection, radiotherapy, chemotherapy, or combined therapy. Prognosis-related survival data included hazard ratio (HR) with 95% confidence intervals (CIs), or curves of overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), disease-specific survival (DSS), metastasis-free survival (MFS), or recurrence-free survival (RFS). Studies were excluded using the criteria of the Cochrane Nonrandomized Studies Methods Group \[[@CR21]\]. Duplicate reports and duplicate cases (with multiple reports of the same study, the most recent publication was selected), and case reports were excluded. We also excluded articles without available full text; articles with incomplete survival data that could not be obtained following communication with the authors; literature reviews; and conference abstracts that lacked sufficient data for meta-analysis quality assessment.

Data extraction {#Sec5}
---------------

We extracted data indicating country or region, author, title, year of publication, journal name, postal or e-mail address, type of research, sample size, age, gender, intervention measure, tumor type, AJCC or UICC cancer stage, lesion site, duration of or lost to follow-up, HR and 95% CI, and NLR cutoff value used to define OS, PFS and DFS. For studies that lacked complete data, the results of multivariate analysis were preferable to those of univariate analysis, but in the absence of multivariate analysis, univariate analysis was accepted. If HRs were not presented, they were calculated from the survival curve data as described by Tierney et al. \[[@CR22]\].

Assessment of included studies {#Sec6}
------------------------------

There are no criteria for evaluation of treatment described in prognostic cohort studies included in systematic reviews. Consequently, each study was assessed by two researchers (YY and XL) following the Newcastle--Ottawa Scale (NOS) for assessing the quality of cohort studies \[[@CR23]\]. The maximum NOS score is 9 points, and studies with scores \> 5 points were classified as high quality. Disagreements were resolved by discussion with a third researcher (HW).

Statistical analysis {#Sec7}
--------------------

Data analysis and processing were carried out using Stata/SE version 13.0 (StataCorp LP, College Station, TX, USA) provided by the Cochrane Collaboration. Disagreements were resolved through discussion. OS, PFS and DFS were evaluated using HR and 95% CI to describe the size of the treatment effect. χ^2^ tests were conducted at α = 0.05, with *P* \< 0.1 as significant. The measure of heterogeneity was *I*^2^, and \< 25% indicated low heterogeneity, 25--50% indicated moderate heterogeneity, and \> 50% indicated high heterogeneity. A fixed effects model was used for studies without heterogeneity, and a random effects model was used for studies with heterogeneity. Meanwhile, subgroup analysis and meta-regression methods were used for heterogeneity analysis. Publication bias was assessed by the Egger test using Stata/SE version 13.0, and the results are shown in funnel plots. Sensitivity analysis was conducted by the meta-trim method.

Results {#Sec8}
=======

Included studies and quality assessment {#Sec9}
---------------------------------------

A total of 122 relevant studies were retrieved; 98 of which were excluded at the initial assessment of titles and abstracts, and the full-text of the remaining 24 was further screened. Nineteen eligible nonrandomized studies \[[@CR24]--[@CR42]\], all of which were cohort studies and included a total of 5475 patients, were included in the analysis. A flowchart of the inclusion and exclusion criteria of each study is shown in Fig. [1](#Fig1){ref-type="fig"}. Two researchers agreed on the 19 studies that were finally selected. All studies included patients with pretreatment NLR and survival data, and the study data and quality assessment results of each study are summarized in Table [1](#Tab1){ref-type="table"}. The Cox regression hazard model used to adjust for potential confounding bias included the majority but not all of the included studies. If multivariate analysis of survival data was unavailable, univariate analysis was adopted for assessment of the survival data. The HNC tumor sites included the mouth, nasal and paranasal sinuses, nasopharynx, larynx and hypopharynx.Fig. 1Literature screening flowchartTable 1Characteristics and quality assessment results for each included publicationsStudyCountryEthnicityTumorsPatients(female/male)Age(range)ResultFollow-up (month)Uni\\MultiCutoff valueNOS ScoreSun et al, 2016 \[[@CR24]\]ChinaAsianNC251 (71\\180)46 (15-76)OS PFS50 (5-84)Multi2.68Wong et al, 2015 \[[@CR25]\]UKCaucasianLSCC140 (19\\121)66 (36-92)OS DFS41 (2-103)Multi3.18Fu et al, 2016 \[[@CR26]\]ChinaAsianLSCC420 (7\\413)60 (33-84)OS CSSungivenMulti2.597An et al, 2011 \[[@CR27]\]ChinaAsianNC363 (89\\274)47 (12-76)DSS MFS62 (2-92)Multi3.737Li et al, 2015 \[[@CR28]\]ChinaAsianNC363 (89\\274)47 (12-76)DSS14.7 (3.22-92.9)Multi2.818He et al, 2012 \[[@CR29]\]ChinaAsianNC1410 (383\\1027)46.1 (13-79)OS PFS41 (2-60)Multi2.747Fang et al, 2013 \[[@CR30]\]ChinaAsianOCSCC226 (19\\207)52.47 (27.0-84.0)OS DFSungivenUni2.446Nakahira et al, 2016 \[[@CR31]\]JapanAsianNS100 (14\\86)65.2 (37-85)CSS37.85 (4-92)Multi38Perisanidis et al, 2013 \[[@CR32]\]AustriaCaucasianOCSCC97 (30\\67)ungivenDSS\> 5 years or until deathMulti1.97Charles et al, 2016 \[[@CR33]\]AustraliaCaucasianHNSCC145 (30\\115)63 (23-86)OS RFS29 (1.5-84)Multi58Tu et al, 2015 \[[@CR34]\]ChinaAsianLSCC141 (4\\137)59 (36-87)OS DFS51 (5-102)Multi2.177Moon et al, 2016 \[[@CR35]\]KoreaAsianHNSCC153 (24\\129)57 (16-78)OS PFS CSS39.5 (4.7-62.6)Multi3.38Rachidi et al, 2016 \[[@CR36]\]AmericaCaucasianHNSCC543 (123\\420)58.8OS64.4 (2-156)Multi4.398Song et al, 2015 \[[@CR37]\]ChinaAsianHSCC146 (10\\136)57.5 (34-89)OS33.2 (2-128)Uni2.37Salim et al, 2015 \[[@CR38]\]TurkeyCaucasianHNSCC79 (8\\71)59 (28-85)OSungivenUni2.936Haddad et al, 2015 \[[@CR39]\]AustraliaCaucasianHNC46 (8\\38)59 (43-81)OS MFS RFS34 (13-47)Uni55Rassouli et al, 2015 \[[@CR40]\]CanadaCaucasianHNSCC273 (75\\198)64 + \_12DFS45 (42-48)Uni4.276Selzer et al, 2015 \[[@CR41]\]AustriaCaucasianHNC318 (121\\247)ungivenOSungivenUni1.587Kim et al, 2016 \[[@CR42]\]KoreaAsianHNC104 (9\\95)58 (20-82)OS PFS39 (4.8-82.5)Multi38*NC* nasopharyngeal carcinoma, *LSCC* laryngeal squamous cell carcinoma, *OCSCC* Oral Cavity Squamous Cell Carcinoma, *HNSCC* Head and neck squamous cell carcinoma, *HSCC* hypopharyngeal squamous cell carcinoma, *HNC* head and neck cancer, *Uni* univariate analysis, *MFS* metastasis-free survival, *Multi* multivariate analysis, *NOS score* Newcastle-Ottawa Scale score, \> 5 meant relative good quality

OS of HNC patients and subgroup analysis by NLR cutoff value {#Sec10}
------------------------------------------------------------

Fourteen studies were included in the meta-analysis of OS. The mortality risk of patients with high NLR was 1.84 times that of patients with low NLR. The difference was significant (HR = 1.84, 95% CI: 1.53--2.23; *P* \< 0.001; heterogeneity, *I*^2^ = 37.2%, *P* = 0.074; Fig. [2a](#Fig2){ref-type="fig"}). Subgroup analysis by NLR cutoff value revealed a higher mortality risk in patients with high NLR compared to those with low NLR. The difference reached significance (2.1 \< cutoff \< 3, HR = 1.71, 95% CI: 1.34--2.17, *P* \< 0.001; heterogeneity, *I*^2^ = 47.6%, *P* = 0.064; 3 ≤ cutoff \< 4, HR = 1.94, 95% CI: 1.235--3.064, *P* = 0.005; heterogeneity, *I*^2^ = 18.3%, *P* = 0.294; cutoff ≥4, HR = 2.414, 95% CI: 1.696--3.436, *P* \< 0.001, heterogeneity: *I*^2^ = 0.0%, *P* = 0.675; Fig. [2b](#Fig2){ref-type="fig"}). In the subgroup-analysis of ethnicity, either Asian \[[@CR24], [@CR26], [@CR29], [@CR30], [@CR34], [@CR35], [@CR37], [@CR42]\] or Caucasian \[[@CR25], [@CR33], [@CR36], [@CR38], [@CR39], [@CR41]\] patients with an evaluated indicated NLR a poor predictor of overall survival. All the results above are shown in Table [2](#Tab2){ref-type="table"}.Fig. 2Forest plots of studies evaluating HRs of the NLR on OS and subgroup based on cutoff valueTable 2Summary of meta-analysis resultsOutcomesVariableNReferencesFixed-effect modelRandom-reffect modelHeterogeneityHR(95%CI)pHR(95%CI)pI2pOSEthnicityAsian8\[[@CR24], [@CR26], [@CR29], [@CR30], [@CR34], [@CR35], [@CR37], [@CR42]\]1.72 (1.46,2.03)\< 0.0011.87 (1.46,2.40)\< 0.00149%0.056Caucasian6\[[@CR25], [@CR33], [@CR36], [@CR38], [@CR39], [@CR41]\]1.85 (1.44,2.37)\< 0.0011.83 (1.34,2.51)\< 0.00126%0.239cutoff value2.1 \< cutoff\< 38\[[@CR24], [@CR26], [@CR29], [@CR30], [@CR34], [@CR37], [@CR38], [@CR41]\]1.63 (1.39,1.91)\< 0.0011.71 (1.43,2.17)\< 0.00147.60%0.0643 \< =cutoff\< 43\[[@CR25], [@CR35], [@CR42]\]1.88 (1.28,2.77)0.0011.95 (1.24,3.06)0.0418.30%0.249cutoff\> = 43\[[@CR33], [@CR36], [@CR39]\]2.41 (1.70,3.44)\< 0.0012.41 (1.70,3.44)\< 0.00100.675DFS4\[[@CR25], [@CR30], [@CR34], [@CR40]\]1.99 (1.46,2.71)\< 0.0011.99 (1.46,2.71)\< 0.00100.457MFS3\[[@CR27], [@CR28], [@CR39]\]1.92 (1.36,2.72)\< 0.0011.92 (1.36,2.72)\< 0.00100.614PFS5\[[@CR24], [@CR29], [@CR35], [@CR38], [@CR42]\]1.60 (1.37,1.87)\< 0.0012.17 (1.20,3.92)0.0191.30%0

PFS and DFS for HNC patients {#Sec11}
----------------------------

The meta-analysis of PFS showed that malignancy was more likely to progress in patients with high NLR than in those with low NLR. The difference was significant (HR = 2.17, 95% CI: 1.20--3.92; *P* \< 0.001; Fig. [3a](#Fig3){ref-type="fig"}). Patients with high NLR had shorter DFS than those with low NLR. The difference reached significance (HR = 2.18, 95% CI: 1.46--3.24; *P* \< 0.001; Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3**a** Forest plots of studies evaluating HRs of the NLR on PFS for head and neck cancer. **b** Forest plots of studies evaluating HRs of the NLR on DFS for head and neck cancer

RFS and MFS for HNC patients {#Sec12}
----------------------------

The meta-analysis of RFS showed that the probability of tumor recurrence after treatment was greater in patients with high NLR than in those with low NLR. The difference was significant (HR = 1.63, 95% CI: 1.09--2.45; *P* = 0.017; heterogeneity, *I*^2^ = 68.7%, *P* = 0.022; Fig. [4a](#Fig4){ref-type="fig"}). There were three studies \[[@CR27], [@CR28], [@CR39]\] that analyzed the correlation between the MFS and NLR. Patients with an elevated NLR had a higher probability of distant metastasis after treatment compared with those with a low NLR, the HR was 1.92 (95% CI: 1.36--2.72; *P* \< 0.001; Fig. [4b](#Fig4){ref-type="fig"}). There was no statistically significant heterogeneity (*I*^*2*^ = 0.0%; *P* = 0.614).Fig. 4**a** Forest plots of studies evaluating HRs of the NLR on RFS for head and neck cancer. **b** Forest plots of studies evaluating HRs of NLR on MFS for head and neck cancer

Publication bias and sensitivity analysis {#Sec13}
-----------------------------------------

In the sensitivity analysis, the trim and fill method was used to combine six sets of data. The corrected data were consistent with the original results (HR = 1.459, 95% CI: 1.174--1.813; *P* = 0.001), indicating stable funnel plots of the meta-analysis (Fig. [5a](#Fig5){ref-type="fig"}). Publication bias was tested by the Egger test (*P* = 0.135), which indicated the absence of publication bias for OS (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5**a** Begg's funnel plot with pseudo 95% confidence limits. **b** Egger's publication bias plot

Discussion {#Sec14}
==========

This study was the first to evaluate the association of NLR in peripheral blood and prognosis in HNC patients. We found that patients with elevated pretreatment NLRs had predictable decreases in OS, DSS and PFS. Also, with increasing NLR cutoff value, mortality risk had a corresponding increasing trend, and patients were increasingly prone to local recurrence and distant metastasis. Our meta-analysis was consistent with previous studies of other malignant tumors. Other meta-analyses revealed better prognosis in patients with colorectal, non-small cell lung, stomach and prostate cancer who had low pretreatment NLR compared to those who had high NLR \[[@CR15]--[@CR19]\]. Pretreatment NLR reflects the status of systemic inflammation and the immune system. However, the cause of poor prognosis in HNC patients with elevated NLR requires further investigation.

Elevation of neutrophils reflects systemic as well as local inflammatory responses. Neutrophils provide a microenvironment conducive to the growth of tumor cells, and they promote tumor progression and invasion of malignant tumor cells \[[@CR43]\]. Neutrophils produce and secrete tumor-promoting growth factors, such as epidermal growth factor, vascular endothelial growth factor, interleukin (IL)-6 and IL-8, that can promote tumor cell activation and facilitate tumor development, invasion and metastasis \[[@CR8], [@CR9]\]. In addition to producing cytokines, neutrophils secrete proteases, such as specific matrix metalloproteinases \[[@CR44], [@CR45]\], cysteine cathepsins \[[@CR46], [@CR47]\] and serine proteases \[[@CR48]\]. These proteases can disrupt the connections between cells and degrade extracellular matrix and basement membrane proteins, thereby facilitating the migration of tumor cells \[[@CR46]--[@CR49]\]. They also promote epithelial cell proliferation, activate dormant tumor cells, and trigger revascularization \[[@CR50]\], forming a link between inflammation and cancer. An increase in the number of neutrophils surrounding cancerous tissue can suppress antitumor immune responses while activating T lymphocytes and natural killer (NK) cells \[[@CR51]\]. Thus, elevation of neutrophils and release of associated cytokines play a role in tumor metastasis and indicate poor prognosis in patients with malignant tumors.

In contrast, a reduction in the number of lymphocytes reflects decreased activity of lymphokine-activated killer cells \[[@CR52]\], with inhibition of the monitoring of the host immune response \[[@CR53]\]. The reduction of lymphocytes includes cells of the innate immune system, such as B lymphocytes, NK cells, CD4^+^ helper T lymphocytes and CD8^+^ cytotoxic T lymphocytes, leading to suppression of the immune response \[[@CR7], [@CR54]\]. Additionally, reduction of the number of lymphocytes results in decreased release of cytokines, such as interferon and tumor necrosis factor-α by tumor macrophages. These cytokines promote apoptosis of tumor cells, which is a key host defense against tumor cell invasion. The collective effect of these changes is attenuation of the antitumor-specific immune system \[[@CR55], [@CR56]\]. There is also a link between the immune system and systemic inflammation. Wong et al. \[[@CR25]\] proposed that chronic inflammation is associated with increased myeloid-derived suppressor cells (MDSCs), which suppress the immune response. They also found that MDSC-mediated immune suppression resulted in dysfunction of the acquired (T cells) and innate (NK cells) immune systems; both of which play a major role in scavenging pathogens and mutant cells under normal conditions.

This study demonstrated that pretreatment NLR can be used to evaluate prognosis in HNC patients, but the optimum NLR cutoff value remains unclear. In the studies we analyzed, the NLR cutoff values ranged from 2.1 to 4.39 and were selected from the means of all patients in each study, or on the basis of previous research. Different studies used different cutoff values, making it difficult to perform the meta-analysis using a single, defined cutoff value. In order to obtain the optimal range of cutoff values, we divided the range into three equal groups for subgroup analysis using NLR cutoff values of 3.0 and 4.0, and a performed a meta-analysis of each subgroup. It is noteworthy that the increase in NLR resulted in similar mortality risks in subgroups 1 and 2, whereas the risk was significantly greater in subgroup 3 than in the other two subgroups. We infer that the prognostic value of NLR in HNC patients is influenced by a range of cutoff values. Optimally, we recommend using a continuous range of NLR values, rather than point values when selecting and comparing NLR cutoff values in future studies.

This meta-analysis had several limitations. First, all included studies were retrospective observational studies, and although multivariate analysis can control for confounding factors to a certain degree, selection bias was inevitable. Second, the NLR values could easily have been affected by infectious diseases, chronic infections, and use of glucocorticoid hormones that might have been present in the same period. Inflammation and NLR elevation are also believed to be associated with coronary heart diseases including acute coronary syndrome \[[@CR57]\]. Interference of the NLR values by potential confounding factors associated with other diseases was thus inevitable. Third, NLR is closely associated with other variables associated with systemic inflammation, such as C-reactive protein and platelet-to-lymphocyte ratio. Interactions among these factors might have resulted in high collinearity in multivariate analysis by the Cox regression model, thereby influencing the evaluation of prognosis by NLR alone. Finally, there was a risk of reporting bias related to the method of retrieving full-text studies. Some studies did not report clinically significant results, and thus did not contribute to the calculated HR values, and some studies only included positive results in the data analysis.

Conclusion {#Sec15}
==========

This meta-analysis showed that HNC patients with elevated pretreatment NLR had poor prognosis and were prone to local invasion and distant metastasis. NLR, which is easily obtained from peripheral blood samples, can help clinicians to determine the prognosis of HNC patients. Preoperative and postoperative interventions to regulate inflammatory and immune responses have a place in the long-term treatment of HNC, but future studies are required to validate the clinical use of NLR.
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